Join us
If you believe in the power of what science can do, 加入澳门葡京赌博游戏，努力突破科学的界限，提供改变生活的药物.
Antibody drug conjugates:
Delivering the next wave of medicines
Delivering the next wave of medicines
Home / R&D / Next generation therapeutics / Antibody drug conjugate
What are antibody drug conjugates?
抗体药物偶联物(Antibody drug conjugates, adc)是一种靶向药物，旨在通过附着在单克隆抗体上的连接物将化疗药物直接输送到癌细胞中. 在这里，澳门葡京赌博游戏解释它们的作用机制和潜在的新型癌症治疗.
How do ADCs work?
ADCs combine a monoclonal antibody (mAb), 它与癌细胞表面的特定靶蛋白结合, with a drug, typically a cytotoxic chemotherapy agent, via a chemical linker.1 After binding to the protein target, ADC被内化到癌细胞中，在那里它释放细胞毒性药物. Unlike conventional chemotherapy, ADCs aim to deliver a drug directly into cancer cells and minimise damage to healthy ones.1
‘Fully human’ mAbs, 它们被改造成含有人类免疫球蛋白基因编码的蛋白质序列, are an ideal delivery platform for ADCs. They are designed to be highly targeted and cell-specific, have a long circulating half-life and offer minimal immunogenicity.1 它们与特定的细胞表面抗原结合，比如癌细胞上的抗原.
将抗体和细胞毒性药物连接在一起的化学“连接物”非常稳定，可以在ADC进入肿瘤之前防止切割(分裂). After binding to the protein target on the cell surface, ADC被内化到癌细胞中，在那里它释放细胞毒性药物.1
抗癌药物(或“有效载荷”)具有通过多种机制导致细胞死亡的能力.1
了解更多抗体药物偶联疗法的作用机制:
The three components of these biologically active drugs, the monoclonal antibody, the linker and the cytotoxic agent, all play a part in defining the therapeutic potential of the ADC.
肿瘤靶向抗体必须精确地识别目标细胞, 因此，细胞表面的受体可以介导抗体药物偶联物的内化. 连接体的稳定性在确保连接体仅在肿瘤细胞内被切割方面起着重要作用, 细胞毒性载荷需要有适当的效力才能发挥其治疗癌症的作用.1
At AstraZeneca, 澳门葡京赌博游戏正在利用澳门葡京赌博游戏在蛋白质工程和药物发现方面的专业知识来优化ADC作用机制的各个方面, 同时使用人工智能驱动的筛选方法来识别临床相关的靶点, 帮助澳门葡京赌博游戏匹配和设计每个ADC与特定肿瘤类型的生物学和敏感性.
澳门葡京赌博游戏的目标是为澳门葡京赌博游戏的ADC产品组合提供广泛的实体和血液恶性肿瘤的治疗选择. To achieve this, it’s critical we continue to optimise target selection, identify novel payloads, 重点开发新的连接剂，努力克服耐药性.
在这个视频中了解更多关于抗体药物偶联物如何导致靶向癌细胞死亡的信息[1:00]:
化疗是癌症治疗的基石，因为它能够针对所有脆弱的细胞. At Oncology R&澳门葡京赌博游戏的目标是通过开发有效和精确的adc来取代传统的化疗, 它们有可能通过直接靶向来杀死肿瘤细胞, while sparing normal cells.
癌细胞靶向:建立分化adc组合
ADCs are a key part of our Oncology R&D strategy. 澳门葡京赌博游戏的愿景是adc取代化疗，成为新型癌症联合治疗方案的支柱.
即使在同一个肿瘤内，癌组织及其细胞表面也有很大差异. 人们认识到需要为广泛的肿瘤特异性设计单克隆抗体, 使癌症治疗能够有效地识别和靶向所有类型的癌细胞, while sparing healthy cells.
We are expanding beyond conventional monotherapy ADCs, which target a single protein on tumour cells, 澳门葡京赌博游戏的多特异性发现平台能够靶向肿瘤细胞上表达的两种或多种靶蛋白. Multispecific ADCs are highly targeted therapies, 有可能提高靶标选择性，减少治疗副作用.1
Leveraging our internal ADC expertise, 澳门葡京赌博游戏正在临床开发的几种adc中展示澳门葡京赌博游戏专有平台的优势. Beyond this, 澳门葡京赌博游戏还与几家外部合作伙伴共同努力，尽快将adc带给患者，并扩大澳门葡京赌博游戏的临床管道.
Collaborate with us
We know that however innovative our science, however effective our medicines and delivery, to achieve all we want to achieve, we cannot do it alone.
Reference:
1. Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4):e00225. Published 2015 Jul 14. Available at: http://onlinelibrary.wiley.com/doi/10.1016/j.febslet.2013.10.015/full. Accessed July 2024.
Veeva ID: Z4-66974
Date of preparation: July 2024